The anti‐obesity and gut microbiota modulating effects of taxifolin in <scp>C57BL</scp>/<scp>6J</scp> mice fed with a high‐fat diet

Su, Hang; Wang, Wenjun; Zheng, Guodong; Yin, Zhong‐Ping; Li, Jingen; Chen, Lingli; Zhang, Qingfeng

doi:10.1002/jsfa.11496

Cited by 27 publications

(26 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thus, no clear significant differences between the F:B or B:F ratio and obesity status was found. In animal studies, the F:B ratio is considered a hallmark of obesity and is therefore used as an outcome to assess the effects of many anti-obesity dietary supplements [ 63 , 64 ] based on their capacity to modulate the gut microbiome by reducing the F:B ratio in the obese. Two systematic reviews [ 24 , 25 ] that included studies measuring the ratio by high-throughput sequencing methods and other methods, such as culture, flow cytometry, and qPCR, among others, found more studies that showed no statistically significant differences in the F:B ratio between obese and non-obese persons than others that did, which is in agreement with our findings.…”

Section: Discussionmentioning

confidence: 99%

Gut Microbiome Composition in Obese and Non-Obese Persons: A Systematic Review and Meta-Analysis

et al. 2021

View full text Add to dashboard Cite

Whether the gut microbiome in obesity is characterized by lower diversity and altered composition at the phylum or genus level may be more accurately investigated using high-throughput sequencing technologies. We conducted a systematic review in PubMed and Embase including 32 cross-sectional studies assessing the gut microbiome composition by high-throughput sequencing in obese and non-obese adults. A significantly lower alpha diversity (Shannon index) in obese versus non-obese adults was observed in nine out of 22 studies, and meta-analysis of seven studies revealed a non-significant mean difference (−0.06, 95% CI −0.24, 0.12, I2 = 81%). At the phylum level, significantly more Firmicutes and fewer Bacteroidetes in obese versus non-obese adults were observed in six out of seventeen, and in four out of eighteen studies, respectively. Meta-analyses of six studies revealed significantly higher Firmicutes (5.50, 95% 0.27, 10.73, I2 = 81%) and non-significantly lower Bacteroidetes (−4.79, 95% CI −10.77, 1.20, I2 = 86%). At the genus level, lower relative proportions of Bifidobacterium and Eggerthella and higher Acidaminococcus, Anaerococcus, Catenibacterium, Dialister, Dorea, Escherichia-Shigella, Eubacterium, Fusobacterium, Megasphera, Prevotella, Roseburia, Streptococcus, and Sutterella were found in obese versus non-obese adults. Although a proportion of studies found lower diversity and differences in gut microbiome composition in obese versus non-obese adults, the observed heterogeneity across studies precludes clear answers.

show abstract

Section: Discussionmentioning

confidence: 99%

Gut Microbiome Composition in Obese and Non-Obese Persons: A Systematic Review and Meta-Analysis

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Previous studies have demonstrated that taxifolin relieved DSS-induced colitis by NF-κB signal way [ 26 ], and Su et al reported that taxifolin, which could improve the obesity symptoms, hepatic steatosis, and gut microbiota dysbiosis in HFD fed C57BL/6 mice [ 27 ]. However, no relevant studies have reported that taxifolin could relieve intestinal mucositis induced by DSS treatment by regulating intestinal flora.…”

Section: Discussionmentioning

confidence: 99%

“…In addition, an increasing amount of research has shown that taxifolin regulates intestinal flora in the colon [ 26 ]. For example, taxifolin can treat metabolic disorders induced by obesity in rats via modulating intestinal flora [ 27 ]. Moreover, it was suggested that inflammation played a critical role in the pathological process of UC, and taxifolin protected DSS-induced UC by inhibiting the inflammatory response [ 26 ].…”

Section: Introductionmentioning

confidence: 99%

“…Moreover, it was suggested that inflammation played a critical role in the pathological process of UC, and taxifolin protected DSS-induced UC by inhibiting the inflammatory response [ 26 ]. Recently, taxifolin was also confirmed to be a regulator by modifying the intestinal flora of mice [ 27 ]. In addition, short-chain fatty acids (SCFAs) can reduce inflammation, and polyphenols may regulate the intestinal microbial ecosystem and promote the production of SCFAs by intestinal bacteria [ 28 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Taxifolin Alleviates DSS-Induced Ulcerative Colitis by Acting on Gut Microbiome to Produce Butyric Acid

Zhang

et al. 2022

Nutrients

View full text Add to dashboard Cite

Taxifolin is a bioflavonoid which has been used to treat Inflammatory Bowel Disease. However, taxifolin on DSS-induced colitis and gut health is still unclear. Here, we studied the effect of taxifolin on DSS-induced intestinal mucositis in mice. We measured the degree of intestinal mucosal injury and inflammatory response in DSS treated mice with or without taxifolin administration and studied the changes of fecal metabolites and intestinal microflora using 16S rRNA. The mechanism was further explored by fecal microbiota transplantation. The results showed that the weight loss and diarrhea score of the mice treated with taxifolin decreased in DSS-induced mice and longer colon length was displayed after taxifolin supplementation. Meanwhile, the expression of GPR41 and GPR43 in the colon was significantly increased by taxifolin treatment. Moreover, the expression of TNF-α, IL-1β, and IL-6 in colon tissue was inhibited by taxifolin treatment. The fecal metabolism pattern changed significantly after DSS treatment, which was reversed by taxifolin treatment. Importantly, taxifolin significantly increased the levels of butyric acid and isobutyric acid in the feces of DSS-treated mice. In terms of gut flora, taxifolin reversed the changes of Akkermansia, and further decreased uncultured_bacterium_f_Muribaculaceae. Fecal transplantation from taxifolin-treated mice showed a lower diarrhea score, reduced inflammatory response in the colon, and reduced intestinal mucosal damage, which may be related to the increased level of butyric acid in fecal metabolites. In conclusion, this study provides evidence that taxifolin can ameliorate DSS-induced colitis by altering gut microbiota to increase the production of SCFAs.

show abstract

“…Desulfovibrionceae are sulfate reducing and lipopolysaccahride (LPS) producing bacteria promoting inflammation and obesity ( 100 , 101 ). In addition, members of Rikenella are also associated with obesity and gut epithelial injury ( 96 , 102 ). More importantly, these changes in the gut microbiome were highly predictive of subsequent protection from HFD-induced weight gain in female mice, while no such association was observed in male DHF-supplemented animals ( 38 ).…”

Section: Discussionmentioning

confidence: 99%

Metabolic protection by the dietary flavonoid 7,8-dihydroxyflavone requires an intact gut microbiome

Sharma

Silva²,

Pfreundschuh³

et al. 2022

Front. Nutr.

View full text Add to dashboard Cite

Background7,8-dihydroxyflavone (DHF) is a naturally occurring flavonoid found in Godmania, Tridax, and Primula species that confers protection against high-fat diet (HFD) induced metabolic pathologies selectively in female mice. We have previously reported that this metabolic protection is associated with early and stable remodeling of the intestinal microbiome, evident in female but not male DHF-supplemented mice. Early changes in the gut microbiome in female DHF-fed mice were highly predictive of subsequent metabolic protection, suggesting a causative association between the gut microbiome and the metabolic effects of DHF.ObjectiveTo investigate a causal association between the gut microbiome and the metabolic effects of DHF using a model of antibiotic-induced gut microbiome ablation.Materials and methodsAge-matched male and female C57Bl6/J mice were given ad libitum access to HFD and drinking water containing vehicle or DHF for 12 weeks. For antibiotic (Abx) treatment, female mice were given drinking water containing a cocktail of antibiotics for 2 weeks prior to HFD feeding and throughout the feeding period. Metabolic phenotyping consisted of longitudinal assessments of body weights, body composition, food, and water intake, as well as measurement of energy expenditure, glucose tolerance, and plasma and hepatic lipids. Protein markers mediating the cellular effects of DHF were assessed in brown adipose tissue (BAT) and skeletal muscle.ResultsMetabolic protection conferred by DHF in female HFD-fed mice was only apparent in the presence of an intact gut microbiome. Abx-treated mice were not protected from HFD-induced obesity by DHF administration. Further, tissue activation of the tropomyosin-related kinase receptor B (TrkB) receptor, which has been attributed to the biological activity of DHF, was lost upon gut microbiome ablation, indicating a requirement for microbial “activation” of DHF for its systemic effects. In addition, we report for the first time that DHF supplementation significantly activates TrkB in BAT of female, but not male, mice uncovering a novel target tissue of DHF. DHF supplementation also increased uncoupling protein 1 (UCP1) and AMP-activated protein kinase (AMPK) protein in BAT, consistent with protection from diet-induced obesity.ConclusionThese results establish for the first time a requirement for the gut microbiome in mediating the metabolic effects of DHF in female mice and uncover a novel target tissue that may mediate these sexually-dimorphic protective effects.

show abstract

The anti‐obesity and gut microbiota modulating effects of taxifolin in C57BL/6J mice fed with a high‐fat diet

Cited by 27 publications

References 43 publications

Gut Microbiome Composition in Obese and Non-Obese Persons: A Systematic Review and Meta-Analysis

Gut Microbiome Composition in Obese and Non-Obese Persons: A Systematic Review and Meta-Analysis

Taxifolin Alleviates DSS-Induced Ulcerative Colitis by Acting on Gut Microbiome to Produce Butyric Acid

Metabolic protection by the dietary flavonoid 7,8-dihydroxyflavone requires an intact gut microbiome

Contact Info

Product

Resources

About